The global artificial intelligence (AI) in cardiology market was valued at USD 1,470.63 million in 2022 and it is predicted to surpass around USD 42,629.90 million by 2032 with a CAGR of 40.03% from 2023 to 2032.
Artificial intelligence (AI) in cardiology refers to the use of machine learning algorithms, computer vision, and other AI technologies in the field of cardiovascular medicine. The aim is to improve diagnosis, treatment planning, and patient outcomes. AI can be used for various applications including image analysis for disease detection and diagnosis, predictive analytics for risk assessment and early intervention, personalized treatment planning based on patient-specific data, streamlining and automating administrative tasks, and enhancing clinical decision-making through real-time data analysis. The use of AI in cardiology is still in the early stages of development, but the potential benefits are significant and include improved accuracy, efficiency, and patient outcomes.
The future of cardiology will be highly based on various innovative digital technologies including artificial intelligence (AI), precision medicine, and the Internet of Things (IoT). The potential of AI in future cardiology is demonstrated by the development of methods for the detection of malignant arrhythmias through wearables, accurate prediction of CVD outcomes, diagnosis, treatment strategies, and outcome prediction for heart failure (HF) patients, and non-invasive diagnosis of coronary artery disease (CAD).
The COVID-19 pandemic has highlighted the need for AI in cardiology and has accelerated its adoption in many healthcare systems. The impact has also increased the demand for AI solutions that can improve patient outcomes and support the effective management of patients with cardiovascular conditions. For example, AI algorithms have been used to identify patients who are at high risk for severe illness from COVID-19 based on factors such as age, underlying health conditions, and vital signs. Additionally, AI has been used to support remote monitoring of patients with cardiovascular diseases, allowing for effective management and early intervention to prevent hospitalization. This has been particularly important during the pandemic as it reduces the risk of exposure to the virus and helps conserve limited hospital resources. The COVID-19 pandemic has accelerated the adoption of AI in cardiology, and its use is expected to increase in the future.
The goal of using AI in cardiology is to improve physician decision-making through data analysis. AI algorithms can help interpret test results such as angiograms and electrocardiograms to quickly detect abnormalities and speed up diagnosis. AI can also predict a patient's risk for chronic heart conditions, allowing for earlier treatment and more informed care plans. There has been significant investment in AI-powered cardiology products in recent years, in the last few years, there have been several considerable industry deals and partnerships in AI cardiology. For instance, in July 2022, the NewYork-Presbyterian hospital, in collaboration with Weill Cornell Medicine and Columbia University VP&S, is working with Cornell Tech and Cornell Bowers CIS to revolutionize cardiovascular health by utilizing AI and machine learning for heart disease prediction and prevention. Cornell University launched the Cardiovascular AI Initiative, a three-year, USD 15 million collaboration with New York Presbyterian Hospital.
Artificial Intelligence in Cardiology Market Segmentations:
|By Component||By End Use||By Application|
Life Science Companies
Ischemic Heart Disease
Artificial Intelligence in Cardiology Market Key Players and Regions Segmentations:
|Key Players||Regions Segmentations|